Infections associated with the use of eculizumab: Recommendations for prevention and prophylaxis

Current Opinion in Infectious Diseases

Volumn 29, Issue 4, 2016, Pages 319-329

  Benamu, Esther ^a   Montoya, José G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

complement system; eculizumab; infection; meningococcus; transplantation

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3; ECULIZUMAB; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY;

ANTIBODY MEDIATED REJECTION; ASPERGILLOSIS; ASPERGILLUS NIGER; ASPERGILLUS NIGER PERITONITIS; COMPLEMENT ACTIVATION; COMPLEMENT COMPONENT C3 GLUMERULOPATHY; COMPLEMENT DISORDER; COMPLEMENT SYSTEM; DELAYED GRAFT FUNCTION; DESENSITIZATION; DISSEMINATED GONOCOCCAL INFECTION; DRUG INDICATION; DRUG USE; GLOMERULOPATHY; GONORRHEA; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOGENICITY; INFECTION; INFECTION PREVENTION; MENINGOCOCCOSIS; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PERITONITIS; PSEUDOMONAS INFECTION; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; VACCINATION; VIRUS INFECTION; CHEMICALLY INDUCED;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MENINGOCOCCAL INFECTIONS;

EID: 84973365170     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000279     Document Type: Review

References (105)

1. Eculizumab-Soliris. Package insert. http://www.accessdata.fda.gov/drug-satfda-docs/label/2007/125166lbl.pdf. [Accessed 4 March 2016]
2. Shaughnessy AF. Monoclonal antibodies: magic bullets with a hefty price tag. BMJ 2012; 345:e8346.
3. Walport MJ. Complement. Firstoftwo parts.NEngl JMed 2001; 344:1058-1066.
4. Mathern DR, Heeger PS. Molecules great and small: the complement system. Clin J Am Soc Nephrol 2015; 10:1636-1650.
5. Pettigrew HD, Teuber SS, Gershwin ME. Clinical significance ofcomplement deficiencies. Ann N Y Acad Sci 2009; 1173:108-123.
6. Devalet B, Mullier F, Chatelain B, et al. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. Eur J Haematol 2015; 95:190-198.
7. Parker CJ, Kar S, Kirkpatrick P. Eculizumab. Nat Rev Drug Discov 2007; 6:515-516.
8. Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011; 117:6786-6792.
9. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008; 111:1840-1847.
10. Schubert J, Hillmen P, Röth A, et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglo-binuria. Br J Haematol 2008; 142:263-272.
11. Helley D, de Latour RP, Porcher R, et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica 2010; 95:574-581.
12. Weitz IC, Razavi P, Rochanda L, et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res 2012; 130:361-368.
13. Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110:4123-4128.
14. Rathbone J, Kaltenthaler E, Richards A, et al. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open 2013; 3:e003573.
15. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. N Engl J Med 2013; 368:2169-2181.
16. Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015; 87:1061-1073.
17. Matar D, Naqvi F, Racusen LC, et al. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation 2014; 98:1205-1212.
18. Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012; 12:3337-3354.
19. Johnson CK, Leca N. Eculizumab use in kidney transplantation. Curr Opin Organ Transplant 2015; 20:643-651.
20. Safa K, Logan MS, Batal I, et al. Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: a case report. Clin Nephrol 2015; 83:125-129.
21. Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014; 14:459-465.
22. Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttrans-plant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 2013; 13:2179-2185.
23. Elsallabi O, Bhatt VR, Dhakal P, et al. Hematopoietic stem cell transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 2016; 22:12-20.
24. Dhakal P, Giri S, Pathak R, Bhatt VR. Eculizumab in transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 2015. [Epub ahead of print]
25. Jodele S, Fukuda T, Vinks A, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangio-pathy. Biol Blood Marrow Transplant 2014; 20:518-525.
26. Jodele S, Laskin BL, Dandoy CE, et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multisystem endothelial injury. Blood Rev 2015; 29:191-204.
27. Gurkan S, Fyfe B, Weiss L, et al. Eculizumab and recurrent C3 glomerulone-phritis. Pediatr Nephrol 2013; 28:1975-1981.
28. Zuber J, Fakhouri F, Roumenina LT, et al., French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8:643-657.
29. Herlitz LC, Bomback AS, Markowitz GS, et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 2012; 23:1229-1237.
30. Bomback AS, Smith RJ, Barile GR, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7:748-756.
31. Eskandary F, Wahrmann M, Mühlbacher J, Böhmig GA. Complement inhibition as potential new therapy for antibody-mediated rejection. Transpl Int 2016; 29:392-402.
32. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11:2405-2413.
33. Cornell LD, Schinstock CA, Gandhi MJ, et al. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant 2015; 15:1293-1302.
34. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9:231-235.
35. Biglarnia A-R, Nilsson B, Nilsson T, et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int 2011; 24:e61-e66.
36. González-Roncero F, Suñer M, Bernal G, et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc 2012; 44:2690-2694.
37. Kocak B, Arpali E, Demiralp E, et al. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports. Transplant Proc 2013; 45:1022-1025.
38. Orandi BJ, Zachary AA, Dagher NN, et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation 2014; 98:857-863.
39. Burbach M, Suberbielle C, Brochériou I, et al. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts. Transplantation 2014; 98:1056-1059.
40. Bentall A, Tyan DB, Sequeira F, et al. Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int 2014; 27:1235-1243.
41. Dawson KL, Parulekar A, Seethamraju H. Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab. J Heart Lung Transplant 2012; 31:1325-1326.
42. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 2012; 298:229-317.
43. Bajic G, Degn SE, Thiel S, Andersen GR. Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J 2015; 34:2735-2757.
44. Pickering MC, Ismajli M, Condon MB, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology 2015; 54:2286-2288.
45. Dumas G, Habibi A, Onimus T, et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood 2016; 127:1062-1064.
46. Smith SG, Watson B, Clark G, Gauvreau GM. Eculizumab for treatment of asthma. Expert Opin Biol Ther 2012; 12:529-537.
47. Howard JF Jr, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 2013; 48:76-84.
48. Kessler RA, Mealy MA, Levy M. Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic. Curr Treat Options Neurol 2016; 18:2.
49. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013; 12:554-562.
50. Wakerley BR, Yuki N. Guillain-Barre syndrome. Expert Rev Neurother 2015; 15:847-849.
51. Misawa S. Novel therapeutic interventions in Guillain-Barre syndrome: review and future perspective. Brain Nerve 2015; 67:1421-1428.
52. Ross SC, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of Neisseria and other infections in an immune deficiency. Medicine 1984; 63:243-273.
53. Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 2010; 23:740-780.
54. Del Rio C, Stephens DS, Knapp JS, et al. Comparison of isolates of Neisseria gonorrhoeae causing meningitis and report of gonococcal meningitis in a patient with C8 deficiency. J Clin Microbiol 1989; 27:1045-1049.
55. Pallares DE, Figueroa JE, Densen P, et al. Invasive Haemophilus influenzae type b infection in a child with familial deficiency of the beta subunit of the eighth component of complement. J Pediatr 1996; 128:102-103.
56. Bleich AT, Sheffield JS, Wendel GD Jr, et al. Disseminated gonococcal infection in women. Obstet Gynecol 2012; 119:597-602.
57. Gleesing J, Chiwane S, Rongkavilit C. Gonococcal septic shock associated with eculizumab treatment. Pediatr Infect Dis J 2012; 31:543.
58. Hublikar S, Maher WE, Bazan JA. Disseminated gonococcal infection and eculizumab: a 'high risk' connection? Sex Transm Dis 2014; 41:747-748.
59. Eculizumab-prescribing information. http://www.accessdata.fda.gov/drug-satfda-docs/label/2007/125166lbl.pdf. [Accessed 4 March 2016]
60. Cohn AC, MacNeil JR, Clark TA, et al., Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1-28.
61. Folaranmi T, Rubin L, Martin SW, et al., Centers for Disease Control (CDC). Use of serogroup B meningococcal vaccines in persons aged >10 years at increased riskfor serogroup b meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:608-612.
62. Platonov AE, Vershinina IV, Kuijper EJ, et al. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine 2003; 21:4437-4447.
63. Platonov AE, Beloborodov VB, Vershinina IV. Meningococcal disease in patients with late complement component deficiency: studies in the U.S.S.R. Medicine 1993; 72:374-392.
64. Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis 2010; 50 (Suppl 2):S54-S65.
65. Wang X, Shutt KA, Vuong JT, et al. Changes in the population structure of invasive Neisseria meningitidis in the United States after quadrivalent meningococcal conjugate vaccine licensure. J Infect Dis 2015; 211:1887-1894.
66. Bouts A, Monnens L, Davin J-C, et al. Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr Nephrol 2011; 26:1919-1920.
67. Rey-Múgica M, de la A, Hernando-Real S, et al. Meningococcemia during eculizumab treatment. Enferm Infecc Microbiol Clin 2013; 31:62.
68. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010; 33:530-541.
69. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006; 103:10834-10839.
70. Trumemba package insert. http://www.fda.gov/downloads/BiologicsBlood-Vaccines/Vaccines/ApprovedProducts/UCM421139.pdf. [Accessed 4 March 2016]
71. Bexsero package insert. http://www.fda.gov/downloads/BiologicsBlood-Vaccines/Vaccines/ApprovedProducts/UCM431447.pdf. [Accessed 4 March 2016]
72. Saez-Llorens X, Aguilera Vaca DC, Abarca K, et al. Immunogenicity and safety of investigational vaccine formulations against meningococcal ser-ogroups A, B, C, W, and Y in healthy adolescents. Hum Vaccin Immunother 2015; 11:1507-1517.
73. Block SL, Szenborn L, Daly W, et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial. Vaccine 2015; 33:2500-2510.
74. Lalwani S, Agarkhedkar S, Gogtay N, et al. Safety and immunogenicity of an investigational meningococcalACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years. Int J Infect Dis 2015; 38:36-42.
75. Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2012; 130:S1-24.
76. Choo S, Zuckerman J, Goilav C, et al. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A+C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine 2000; 18:2686-2692.
77. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27 (Suppl 2):B112-B116.
78. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection: serum bactericidal antibody activity. Vaccine 2005; 23:2222-2227.
79. Sikkema DJ, Friedman KE, Corsaro B, et al. Relationship between serum bactericidal activity and serogroup-specific immunoglobulin G concentration for adults, toddlers, and infants immunized with Neisseria meningitidis serogroup C vaccines. Clin Diagn Lab Immunol 2000; 7:764-768.
80. Burrage M, Robinson A, Borrow R, et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun 2002; 70:4946-4954.
81. Cohn A, MacNeil J. The changing epidemiology of meningococcal disease. Infect Dis Clin North Am 2015; 29:667-677.
82. Santolaya ME, O'Ryan M, Valenzuela MT, et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother 2013; 9:2304-2310.
83. Struijk GH, Bouts AHM, Rijkers GT, et al. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant 2013; 13:819-820.
84. Krid S, Roumenina LT, Beury D, et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant 2012; 12:1938-1944.
85. Patir P, Isik Y, Turk Y, et al. Necrotizing fasciitis in paroxysmal nocturnal hemoglobinuria. Case Rep Hematol 2015; 2015:908087.
86. Webb BJ, Healy R, Child B, et al. Recurrent infection with Pseudomonas aeruginosa during eculizumab therapy in an allogeneic hematopoietic stem cell transplant recipient. Transpl Infect Dis 2016; 18:312-314.
87. Bonfante L, Nalesso F, Cara M, et al. Aspergillus fumigatus peritonitis in ambulatory peritoneal dialysis: a case report and notes on the therapeutic approach. Nephrology 2005; 10:270-273.
88. Vellanki VS, Bargman JM. Aspergillus niger peritonitis in a peritoneal dialysis patient treated with eculizumab. Ren Fail 2014; 36:631-633.
89. Kozel TR. Activation of the complement system by pathogenic fungi. Clin Microbiol Rev 1996; 9:34-46.
90. Speth C, Rambach G, Würzner R, Lass-Flörl C. Complement and fungal pathogens: an update. Mycoses 2008; 51:477-496.
91. Hector RF, Yee E, Collins MS. Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis. Infect Immun 1990; 58:1476-1478.
92. Stoermer KA, Morrison TE. Complement and viral pathogenesis. Virology 2011; 411:362-373.
93. Dunkelberger JR, Song W-C. Role and mechanism of action of complement in regulating T cell immunity. Mol Immunol 2010; 47:2176-2186.
94. Borhan WM, Dababo MA, Thompson LDR, et al. Acute necrotizing herpetic tonsillitis: a report of two cases. Head Neck Pathol 2015; 9:119-122.
95. Gómez-Cibeira E, Ivanovic-Barbeito Y, Gutiérrez-Martínez E, et al. Eculizu-mab-related progressive multifocal leukoencephalopathy. Neurology 2016; 86:399-400.
96. Gatault P, Brachet G, Ternant D, et al. Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule. MAbs 2015; 7:1205-1211.
97. Xie L, Nester CM, Reed AI, et al. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Transplant Proc 2012; 44:3037-3040.
98. Cugno M, Gualtierotti R, Possenti I, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014; 12:1440-1448.
99. Blom AM, Osterborg A, Mollnes TE, Okroj M. Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. Mol Immunol 2015; 66:164-170.
100. Volokhina EB, van de Kar NCAJ, Bergseth G, et al. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol 2015; 160:237-243.
101. Noris M, Galbusera M, Gastoldi S, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014; 124:1715-1726.
102. Jodele S, Fukuda T, Mizuno K, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangio-pathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2016; 22:307-315.
103. Cullinan N, Gorman KM, Riordan M, et al. Case report: benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome. Pediatrics 2015; 135:e1506-e1509.
104. Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 2015; 125:775-783.
105. Cataland SR. Eculizumab therapy. Biol Blood Marrow Transplant 2014; 20:438-439.